Preclinical evaluation of 5-ALA-based PDT for the treatment of canine urinary bladder cancer: fluorescence distribution and response of normal urinary bladder tissue

Michael D. Lucroy D.V.M.; George M. Peavy D.V.M.; Tisha Ridgway; Russell G. Higbee; Gregory A. Campbell; Tiffany A. Healey; Kenneth Eugene Bartels D.V.M.

doi:10.1117/12.440961

17 June 2002 Preclinical evaluation of 5-ALA-based PDT for the treatment of canine urinary bladder cancer: fluorescence distribution and response of normal urinary bladder tissue

Michael D. Lucroy D.V.M., George M. Peavy D.V.M., Tisha Ridgway, Russell G. Higbee, Gregory A. Campbell, Tiffany A. Healey, Kenneth Eugene Bartels D.V.M.

Author Affiliations +

Proceedings Volume 4609, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XII; (2002) https://doi.org/10.1117/12.440961
Event: International Symposium on Biomedical Optics, 2002, San Jose, CA, United States

Abstract

Photodynamic therapy (PDT) is a potential improvement over conventional therapy for urinary bladder cancer, especially using the pro-photosensitizer 5-aminolevulinic acid (ALA), which is metabolized to its active form, protoporphyrin IX (PpIX), within both normal and neoplastic epithelial tissue. The purpose of this study was to evaluate ALA-based PDT in healthy dogs as a prelude to treating dogs with transitional cell carcinoma of the urinary bladder. Methods: Twelve dogs were given oral ALA at 0, 30, 60, or 90 mg/kg. Four hours later, the dogs were sacrificed and bladder tissue was collected and frozen for low-intensity fluorescence microscopy. Fifteen dogs were given oral ALA at 0, 30, 60, or 90 mg/kg and anesthetized four hours later. The trigone was irradiated with 635 nm laser light. All dogs were necropsied after PDT (48 h or 21 d). Results: PpIX fluorescence was confined to the urinary bladder mucosa with no detectable fluorescence in the muscularis or serosa. Histopathological lesions after PDT were limited to mild inflammation. Conclusions: Oral ALA appears to be well tolerated by healthy dogs at the dosages used. Because PpIX fluorescence was confined to the mucosa, ALA-based PDT may be a useful treatment for canine lower urinary tract neoplasia.

Citation Download Citation

Michael D. Lucroy D.V.M., George M. Peavy D.V.M., Tisha Ridgway, Russell G. Higbee, Gregory A. Campbell, Tiffany A. Healey, and Kenneth Eugene Bartels D.V.M. "Preclinical evaluation of 5-ALA-based PDT for the treatment of canine urinary bladder cancer: fluorescence distribution and response of normal urinary bladder tissue", Proc. SPIE 4609, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XII, (17 June 2002); https://doi.org/10.1117/12.440961

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available